company background image
OLMA logo

Olema Pharmaceuticals NasdaqGS:OLMA Stock Report

Last Price

US$11.32

Market Cap

US$626.2m

7D

-2.0%

1Y

219.8%

Updated

28 Mar, 2024

Data

Company Financials +

Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stock Report

Market Cap: US$626.2m

OLMA Stock Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

OLMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Olema Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Olema Pharmaceuticals
Historical stock prices
Current Share PriceUS$11.32
52 Week HighUS$17.79
52 Week LowUS$3.00
Beta2.14
1 Month Change-17.49%
3 Month Change-19.32%
1 Year Change219.77%
3 Year Change-67.08%
5 Year Changen/a
Change since IPO-76.90%

Recent News & Updates

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Recent updates

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Jun 11
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Mar 01
Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Oncology grants stock options for 58.3K shares

Oct 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Shareholder Returns

OLMAUS BiotechsUS Market
7D-2.0%0.9%0.4%
1Y219.8%10.3%28.8%

Return vs Industry: OLMA exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: OLMA exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is OLMA's price volatile compared to industry and market?
OLMA volatility
OLMA Average Weekly Movement11.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: OLMA's share price has been volatile over the past 3 months.

Volatility Over Time: OLMA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200674Sean Bohenhttps://olema.com

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.

Olema Pharmaceuticals, Inc. Fundamentals Summary

How do Olema Pharmaceuticals's earnings and revenue compare to its market cap?
OLMA fundamental statistics
Market capUS$626.25m
Earnings (TTM)-US$96.65m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OLMA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$96.66m
Earnings-US$96.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.73
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did OLMA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.